In this Q&A with @DrugTargetRev, our cofounder Dr. Lev Becker shares more about how N17350 selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms.
https://t.co/olBshgdumy
We will be presenting at #ImmunoSeries on our lead drug candidate, N17350, which is an emerging therapeutic modality that selectively kills any #cancer cells and stimulates anti-tumor immunity.
For the full @ImmunoOncConf agenda visit: https://t.co/nHw6Qc9LDW
We will be presenting at #SITC23 our latest data on our lead drug candidate, N17350, showing a unique combination of potent and selective #cancer killing activity to eradicate #tumors independent of genetics or anatomical origin.
https://t.co/pvUMdERFk7
The University of Chicago Medicine’s Cancer Program is one of the top-ranked specialties in the nation and the best in Illinois, according to the latest U.S. News & World Report.
https://t.co/1Nxqtr0DGE
We’re excited to present today at #AACR23 new preclinical data for our lead candidate N17350, which possesses unique therapeutic characteristics and may be a major new treatment modality in #immunooncology.
See the press release & poster here: https://t.co/Rezp8qgnYN
Check out 60 minutes tonight. Thanks to hardworking neuroscientists, amazing patients and especially monkeys, BCI is helping people every day. @Wa_NPRC@slimanjbensmaia https://t.co/DeN1MbuuM9
Excited to be attending the 2023 Weinman Symposium in Honolulu. One of my favourite conferences in terms of speakers, venue, and organisation. Aloha. https://t.co/INkkaFYDzl
Today we disclosed our 1st drug development candidate, N17350, a first-in-class biologic to leverage #neutrophil biology and broadly treat #cancer. We also expanded our platform to design new therapeutics to modulate M2-like tumor-associated #macrophages.
https://t.co/K1ej0hi7YK
Tenure Track Assistant Professorship in the Ben May Department for Cancer Research - looking for talented applicants focused on Mechanistic Aspects of Prostate Cancer or Related Areas. EOE/Vet/Disability. Apply here:
https://t.co/aEAOsJCNDo
Excited to be participating in @AIC2021 tomorrow. My first in-person conference in 2 years. Looking forward to (safely) interacting with a fantastic line up of immunologists and trainees.
https://t.co/U02Ev5Y2JY
Excited to share a collaborative paper with @KrishnanYamuna in @NatureNano. Read on to see how we identified a new #innateimmune defect in #cancer and used #DNAnanotechnology to correct it. Congratulations to @PurrChangC, @deeyakc, and all coauthors. https://t.co/N3lEYGPHL8